Screening healthy volunteers for malaria vaccine and drug studies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to recruit healthy volunteers to determine their eligibility for future research on malaria vaccines, antimalarial drugs, and controlled human malaria challenges. Participants will undergo a prescreening process followed by a detailed medical history assessment and physical examination. The goal is to build a pool of qualified volunteers for ongoing and future malaria-related clinical trials conducted by the Laboratory of Malaria Immunology and Vaccinology. This initiative addresses the urgent need for effective malaria prevention and treatment options.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

All of the following criteria must be fulfilled for a subject to participate in this trial:

1. Age \>= 18 and \<= 50 years.
2. In good general health and without clinically significant medical history
3. Reliable access to the clinical trial center and available in the area for more than 1 year
4. Females of childbearing potential must be willing to undergo periodic pregnancy testing and use reliable contraception per protocol when enrolled into LMIV clinical trials (protocol-specific requirements)

EXCLUSION CRITERIA:

A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:

1. Pregnant, breastfeeding, or planned pregnancy in the upcoming year.
2. Hemoglobin, white blood cell (WBC), platelets, alanine transaminase (ALT), and creatinine (Cr) outside of local lab normal range (subjects may be included at the investigator's discretion for "not clinically significant" values outside of normal range).
3. Anticipated use during the study period, or use within the following periods prior to enrollment:

   1. Investigational malaria vaccine within the last five years
   2. Chronic systemic immunosuppressive medications (e.g., cytotoxic medications, oral/parental corticosteroids \> 0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis is allowed.
   3. Recurrent receipt of blood products or immunoglobulins
4. History of:

   1. Sickle cell disease
   2. Splenectomy or functional asplenia
   3. Systemic anaphylaxis
   4. Uncontrolled psoriasis or porphyria
5. Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:

   1. A process that would affect the immune response, or requires medication that affects the immune response.
   2. Any contraindication to repeated phlebotomy.
6. History of or known active cardiac disease including:

   1. prior myocardial infarction (heart attack)
   2. angina pectoris
   3. congestive heart failure
   4. valvular heart disease
   5. cardiomyopathy
   6. pericarditis
   7. stroke or transient ischemic attack
   8. exertional chest pain or shortness of breath
   9. other heart conditions under the care of a doctor
7. Infection with HIV, hepatitis B, and/or hepatitis C
8. Psychiatric condition that precludes compliance with the protocol including but not limited to:

   1. Psychosis within the past 3 years
   2. Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years
9. Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the discretion of the PI
10. Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject's ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: David M Cook, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
• Study coordinator: David M Cook, M.D.
• Email: cookdm@mail.nih.gov
• Phone: (240) 627-3066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lotilaner safety and blood activity in healthy adults in Mali

  This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.

  Recruiting Phase 1 Medicines for Malaria Venture · Bamako · NCT07758985

• See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5

  This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.

  Recruiting at 12 sites Clinton Health Access Initiative Inc. · Boromo, Boucle Mouhoun and 20 other locations · NCT07749911

• Do malaria vaccines lower the risk of invasive non-typhoidal Salmonella in young children?

  This study will see if the R21/Matrix-M malaria vaccine lowers the chance of invasive non-typhoidal Salmonella disease in children under 5 who come to health facilities with fever in the Kisantu Health Zone (DRC).

  Recruiting International Vaccine Institute · Kinshasa · NCT07416461

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Lower-dose and alternate-schedule RTS,S malaria vaccine for young children

  This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Kigali and 1 other locations · NCT07036159

• Optimizing malaria and HIV treatment for children in Busia and Kampala

  We will test whether dolutegravir affects growth and how it interacts with common malaria medicines in children with and without HIV, following them for two years in Busia and Kampala.

  Recruiting at 2 sites Phase 4 Yale University · Kampala and 1 other locations · NCT06967519

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.